Question 1

What are the potential benefits of participating in this trial compared to standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

Question 2

How will the treatments be administered, and what can I expect during the visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I be aware of from SHR-A1811 and Adebrelimab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens after the six cycles of treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer clinical trial (NCT06340230). Contact the study team or your healthcare provider for specific answers.

What this study is about